WADA The 2023 Monitoring Program
The following substances are placed on the 2022 Monitoring Program*:
- Anabolic Agents:
In and Out-of-Competition: Ecdysterone
- Peptides Hormones, Growth Factors, Related Substances, and Mimetics:
In and Out-of-Competition: Gonadotrophin-releasing hormone (GnRH) analogs in females under 18 years only.
- Beta-2 Agonists: In and Out-of-Competition: Salmeterol and vilanterol below the Minimum Reporting Level.
- Hypoxen (polyhydroxyphenylene thiosulfonate sodium):
In and Out-of-Competition
In-Competition only: Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol and synephrine.
In-Competition only: Codeine, dermorphin (and its analogs), hydrocodone and tramadol.
* The World Anti-Doping Code (Article 4.5) states: “WADA, in consultation with Signatories and governments, shall establish a monitoring program regarding substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect potential patterns of misuse in sport.”